A 22-year experience with pancreatic resection for metastatic renal cell carcinoma

Blaire Anderson, Gregory A. Williams, Dominic E. Sanford, Jingxia Lu, Leigh A. Dageforde, Chet W. Hammill, Ryan C. Fields, William G. Hawkins, Steven M. Strasberg, Majella B. Doyle, William C. Chapman, Adeel S. Khan

Research output: Contribution to journalArticlepeer-review

11 Scopus citations


Background: The pancreas is a rare site of metastases, although metastatic renal cell carcinoma (mRCC) is the most commonly reported secondary tumor. Pancreatectomy has been described in selected patients with localized metastases, but long-term benefit remains poorly defined. Methods: A retrospective review of a prospectively maintained database was performed to evaluate the outcomes of patients undergoing pancreatectomy for mRCC at a tertiary care center from 1995–2017. Postoperative complications were evaluated using the Modified Accordion Grading System (MAGS) and Kaplan–Meier curves and log-rank tests were utilized for survival analysis. Results: 29 patients underwent pancreatectomy for mRCC including 15 distal pancreatectomies (DP), 10 pancreaticoduodenectomies (PD) and 4 total-pancreatectomies (TP). The mean age was 67 ± 8 years, and 15 were male. The median time from index nephrectomy to pancreatectomy was 8 (IQR: 3.72–12.2) years. There was no 90 Day post-pancreatectomy mortalities and the morbidity incidence included 13 Minor MAGS and 8 Severe MAGS complications respectively. Post-pancreatectomy disease specific survival at 2- and 4-years were 89% and 80% with 12 patients being alive at last follow up. Conclusions: Pancreatic resection can be safely performed in select patients with localized mRCC with favorable long-term outcomes.

Original languageEnglish
Pages (from-to)312-317
Number of pages6
Issue number2
StatePublished - Feb 2020


Dive into the research topics of 'A 22-year experience with pancreatic resection for metastatic renal cell carcinoma'. Together they form a unique fingerprint.

Cite this